DBV Technologies Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
179
- Stock Symbol
-
DBV
- Share Price
-
$1.95
- (As of Thursday Closing)
DBV Technologies General Information
Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Contact Information
Website
www.dbv-technologies.comCorporate Office
- Bâtiment IRO
- 107 Av. de la République
- 92320 Chatillon
- France
Corporate Office
- Bâtiment IRO
- 107 Av. de la République
- 92320 Chatillon
- France
DBV Technologies Timeline
DBV Technologies Stock Performance
As of 19-Nov-2026, DBV Technologies’s stock price is $1.95. Its current market cap is $612M with 314M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.95 | $1.92 | $1.72 - $5.29 | $612M | 314M | 1.16M | -$0.60 |
DBV Technologies Financials Summary
As of 30-Sep-2026, DBV Technologies has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 573,035 | 734,467 | 30,887 | 43,249 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (205,463) | (143,863) | (109,044) | (67,272) |
| Net Income | (207,347) | (146,947) | (113,918) | (72,726) |
| Total Assets | 215,400 | 233,718 | 65,658 | 182,986 |
| Total Debt | 7,500 | 7,994 | 7,797 | 6,553 |
DBV Technologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
DBV Technologies Comparisons
Industry
Financing
Details
DBV Technologies Competitors (44)
One of DBV Technologies’s 44 competitors is Adocia, a Formerly VC-backed company based in Lyon, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adocia | Formerly VC-backed | Lyon, France | ||||
| NuvOx Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| ArriVent Biopharma | Formerly VC-backed | Newtown Square, PA |
DBV Technologies Patents
DBV Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024402685-A1 | Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease | Pending | 21-Dec-2023 | ||
| EP-4735036-A1 | Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease | Active | 21-Dec-2023 | ||
| EP-4735036-B1 | Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease | Active | 21-Dec-2023 | ||
| EP-4786006-A2 | Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease | Pending | 21-Dec-2023 | ||
| EP-4786006-A3 | Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease | Pending | 21-Dec-2023 | A61K39/35 |
DBV Technologies Signals
DBV Technologies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
DBV Technologies ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
DBV Technologies Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Dbv Pharma | Paris, France | 2018 |
DBV Technologies FAQs
-
When was DBV Technologies founded?
DBV Technologies was founded in 2002.
-
Where is DBV Technologies headquartered?
DBV Technologies is headquartered in Chatillon, France.
-
What is the size of DBV Technologies?
DBV Technologies has 179 total employees.
-
What industry is DBV Technologies in?
DBV Technologies’s primary industry is Biotechnology.
-
Is DBV Technologies a private or public company?
DBV Technologies is a Public company.
-
What is DBV Technologies’s stock symbol?
The ticker symbol for DBV Technologies is DBV.
-
What is the current stock price of DBV Technologies?
As of 19-Nov-2026 the stock price of DBV Technologies is $1.95.
-
What is the current market cap of DBV Technologies?
The current market capitalization of DBV Technologies is $612M.
-
Who are DBV Technologies’s competitors?
Adocia, NuvOx Therapeutics, Ayala Pharmaceuticals, Dicerna Pharmaceuticals, and ArriVent Biopharma are some of the 44 competitors of DBV Technologies.
-
What is DBV Technologies’s annual earnings per share (EPS)?
DBV Technologies’s EPS for 12 months was -$0.60.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process